 |
|
|
|
|
Investors
Argos Therapeutics, Inc. is developing breakthrough immunotherapies
that target unique features of a patient’s disease. This new generation
of personalized cancer and infectious disease therapeutics trains the
immune system to recognize and attack the disease. Argos’ scientific
leadership in RNA-loaded dendritic cells and advanced manufacturing processes
provide a platform to tackle virtually all forms of cancers and infectious
diseases.
The Company has a number of prominent corporate partnerships,
licensing agreements and research collaborations in place to advance
its development and commercialization plans. Argos continues to establish
new relationships with investors and potential business partners. To
date, the Company has raised approximately $50 million from investors.
If
you are interested in discussing investment opportunities with Argos Therapeutics,
please contact us at businessdev@argostherapeutics.com.
|
|
 |
|
